(PharmaNewsWire.Com, September 13, 2017 ) Growth hormone deficiency (GHD) is a rare endocrine disorder characterized by inadequate secretion of growth hormone (GH) from the anterior pituitary gland. It is a heterogeneous disorder that may present in childhood (pediatric GHD) or later in adult life (adult GHD). Reduced GH secretion predominantly results in stunted linear growth in children; therefore, the standard-of-care GH replacement therapy serves to normalize height in children. Adults with GHD generally demonstrate biochemical abnormalities, which can also be successfully treated with recombinant GH. GlobalData estimates the 2016 sales for GHD at approximately $1.42 billion across the 7MM covered in this report. The market will grow moderately at a CAGR of 3.9% during the 10-year forecast period, generating sales of approximately $2.08 billion at the end of 2026. The US market is expected to grow the fastest of the three regions, recording a CAGR of 4.4% and generating around 69% of global sales in 2026. This growth will be driven primarily by the highly anticipated arrivals of the long-acting GHs and the resultant increase in compliance with and adherence to therapy. Although the more convenient long-acting GHs are expected to markedly change the GHD treatment landscape, and eventually replace daily GHs, market growth will be restricted by the continued negotiations between distributers and payers, which is expected to keep the prices of these new drugs at bay.
-Overall, the greatest unmet need in the GHD space is the issue with treatment adherence and compliance. There are other prominent unmet needs highlighted by the Key Opinion Leaders (KOLs). What are these-Will the pipeline drugs fulfil these unmet needs of the market- -The 10-year forecast period will mark the launch of four pipeline long-acting GH drugs. How will the sales of the existing drugs be impacted-Which of the pipeline drugs will have the highest peak sales at the highest CAGR, and why- -What are the roles of payers in this highly competitive disease space-How does this affect market shares of the GH brands-What are the chances of reimbursement for the long-acting GH drugs in pipeline-
-Overview of GHD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. -Annualized GHD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026. -Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GHD therapeutics market. -Pipeline analysis-comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. -Analysis of the current and future market competition in the global GHD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The report will enable you to- -Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. -Develop business strategies by understanding the trends shaping and driving the global GHD therapeutics market. -Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GHD therapeutics market in future. -Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. -Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. -Track drug sales in the 7MM GHD therapeutics market from 2016-2026. -Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Inquire for Report at http://www.reportsweb.com/inquiry&RW00011016464/sample
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: